National Cancer Institute; Notice of Meeting, 37451-37452 [2010-15785]
Download as PDF
Federal Register / Vol. 75, No. 124 / Tuesday, June 29, 2010 / Notices
animal health and (2) limiting such
drugs to uses in food-producing animals
that include veterinary oversight or
consultation. Developing strategies for
reducing antimicrobial resistance is
critically important for protecting both
public and animal health. Collaboration
involving both the public and animal
health communities on the development
and implementation of such strategies is
needed to assure that the public health
is protected while also assuring that the
health needs of animals are addressed.
This draft guidance discusses FDA’s
general public health concerns
regarding the potential impact of certain
uses of medically important
antimicrobial drugs in food-producing
animals on the development of
antimicrobial resistance, and provides
two broad recommendations regarding
such use. The agency intends to issue
further guidance in the near future to
provide more specific information on
approaches for implementing the
recommendations outlined in this draft
guidance.
II. Significance of Guidance
This level 1 draft guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent the agency’s
current thinking on this topic. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
III. Paperwork Reduction Act of 1995
FDA concludes that there are no
collections of information under the
Paperwork Reduction Act of 1995.
emcdonald on DSK2BSOYB1PROD with NOTICES4
IV. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
IV. Electronic Access
Persons with access to the Internet
may obtain the draft guidance at either
https://www.fda.gov/AnimalVeterinary/
default.htm or https://
www.regulations.gov.
VerDate Mar<15>2010
19:55 Jun 28, 2010
Jkt 220001
Dated: June 10, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–15289 Filed 6–28–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neuroendocrinology and Fetal
Alcohol.
Date: July 13, 2010.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Michael Selmanoff, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3134,
MSC 7844, Bethesda, MD 20892, 301–435–
1119, mselmanoff@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Language and Communication.
Date: July 14, 2010.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Dana Jeffrey Plude, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3176,
MSC 7848, Bethesda, MD 20892, 301–435–
2309, pluded@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
37451
Name of Committee: Center for Scientific
Review Special Emphasis Panel; ARRA:
Member Conflict in Cognition and Perception
Competitive Revisions.
Date: July 14, 2010.
Time: 12 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Dana Jeffrey Plude, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3176,
MSC 7848, Bethesda, MD 20892, 301–435–
2309, pluded@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cancer Drug Development and
Therapeutics.
Date: July 19–20, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Hungyi Shau, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6186,
MSC 7804, Bethesda, MD 20892, 301–357–
9099, Hungyi.Shau@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 23, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–15784 Filed 6–28–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Director’s
Consumer Liaison Group.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
E:\FR\FM\29JNN1.SGM
29JNN1
37452
Federal Register / Vol. 75, No. 124 / Tuesday, June 29, 2010 / Notices
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Director’s Consumer Liaison Group.
Date: July 27–29, 2010.
Time: 2 p.m. to 1 p.m.
Agenda: Welcome, Challenges in
Biospecimen Collection; Expert Panel on
Innovative Approaches to Engaging the
Community around Biospecimen Collection,
Board Discussion About Innovative
Approaches to Engaging the Community
around Biospecimen Collection.
Place: Jackson Federal Building, 915
Second Ave, Room 440, Seattle, WA 98174.
Contact Person: Benjamin Carollo, MPA,
Advocacy Relations Manager, Office Of
Advocacy Relations, Building 31, Room
10A30, 31 Center Drive, MSC 2580, National
Cancer Institute, NIH, DHHS, Bethesda, MD
20892–2580, 301–496–0307,
CAROLLOB@MAIL.NIH.GOV.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/dclg/dclg.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: June 23, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–15785 Filed 6–28–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Science Board Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
emcdonald on DSK2BSOYB1PROD with NOTICES4
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Science Board to
the Food and Drug Administration
(Science Board).
General Function of the Committee:
The Science Board provides advice
primarily to the Commissioner of Food
and Drugs and other appropriate
VerDate Mar<15>2010
19:55 Jun 28, 2010
Jkt 220001
officials on specific complex and
technical issues, as well as emerging
issues within the scientific community
in industry and academia. Additionally,
the Science Board provides advice to
the agency on keeping pace with
technical and scientific evolutions in
the fields of regulatory science, on
formulating an appropriate research
agenda, and on upgrading its scientific
and research facilities to keep pace with
these changes. It will also provide the
means for critical review of agency
sponsored intramural and extramural
scientific research programs.
Date and Time: The meeting will be
held on Monday, August 16, 2010, from
8 a.m. to 3:30 p.m.
Location: Bethesda Marriott, 5151
Pooks Hill Rd., Bethesda, MD 20814.
Contact Person: Donna Mentch, Office
of Medical and Scientific Programs,
Office of the Commissioner, Food and
Drug Administration, White Oak Bldg.
32, 10903 New Hampshire Ave., Silver
Spring, MD 20993, 301–796–8523, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code 301–
451–2603. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On August 16, 2010, the
Science Board will hear about and
discuss a final report from its
subcommittee reviewing research at the
Center for Food Safety and Applied
Nutrition (CFSAN). The Science Board
will hear about an interim report from
the subcommittee to review the
Pharmacovigilance Program at the
Center for Drug Evaluation and Research
(CDER). The Science Board will also
hear about and discuss JANUS, FDA
supported Data Standard Comparative
Effectiveness Research, and FDA’s
nanotechnology research program.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
PO 00000
Frm 00078
Fmt 4703
Sfmt 9990
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 9, 2010. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 2, 2010. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 3, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Donna
Mentch, at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 24, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–15709 Filed 6–28–10; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\29JNN1.SGM
29JNN1
Agencies
[Federal Register Volume 75, Number 124 (Tuesday, June 29, 2010)]
[Notices]
[Pages 37451-37452]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15785]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Director's Consumer Liaison Group.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should
[[Page 37452]]
notify the Contact Person listed below in advance of the meeting.
Name of Committee: National Cancer Institute Director's Consumer
Liaison Group.
Date: July 27-29, 2010.
Time: 2 p.m. to 1 p.m.
Agenda: Welcome, Challenges in Biospecimen Collection; Expert
Panel on Innovative Approaches to Engaging the Community around
Biospecimen Collection, Board Discussion About Innovative Approaches
to Engaging the Community around Biospecimen Collection.
Place: Jackson Federal Building, 915 Second Ave, Room 440,
Seattle, WA 98174.
Contact Person: Benjamin Carollo, MPA, Advocacy Relations
Manager, Office Of Advocacy Relations, Building 31, Room 10A30, 31
Center Drive, MSC 2580, National Cancer Institute, NIH, DHHS,
Bethesda, MD 20892-2580, 301-496-0307, CAROLLOB@MAIL.NIH.GOV.
Information is also available on the Institute's/Center's home page:
deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: June 23, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-15785 Filed 6-28-10; 8:45 am]
BILLING CODE 4140-01-P